9 February 2009: NorDiag has won a tender offer for sale of a high throughput ("Bullet") instrument and reagents to Lund University Hospital in Sweden. The instrument will be used for bacterial DNA isolation, including MRSA from clinical samples.

The sales value of the contract including yearly reagent use is estimated to be SEK 2,4 million.  MRSA is a very common hospital infection, and the test is one of NorDiag's new applications.

Mårten Wigstøl, CEO in NorDiag, comments: -"We have once more demonstrated that we are able to compete both on quality and price. Most of our sales so far have been in the field of sexually transmitted infections (STI), but we are now seeing more and more customers that use our reagents connected to detection of MRSA.  This proves that our multiple application strategy going forward, fits the customer's needs."

NorDiag has started to launch more applications on its "Bullet" instrument platform. NorDiag has already established a solid foothold and market share in the Scandinavian STI market and the strategy is to replicate this success for other applications as well, where MRSA is one of the candidates. NorDiag has now 3 customers in Sweden that use reagents for MRSA detection on a routine basis.

Contact:             
CEO Mårten Wigstøl              
Phone: +47 91165775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The company's core competence is isolation of bacterial and human DNA from difficult clinical samples, and the company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here